ADAG
Adagene Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.29
P/S
1578.29
EV/EBITDA
-3.00
DCF Value
$1.64
FCF Yield
-21.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1088.5%
Operating Margin
-41197.5%
Net Margin
-37235.6%
ROE
-86.9%
ROA
-57.8%
ROIC
-94.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-13.5M | $-0.36 |
| Q4 2024 | $103.2K | $-24.9M | $-0.71 |
| FY 2024 | $103.2K | $-33.4M | $-0.95 |
| Q2 2024 | $0.00 | $-8.5M | $-0.24 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CN
Exchange
NASDAQ
Beta
0.71
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.